DR. SETH MICHAELS POLLACK MD NPI 1528234143

NPI Details

DR. Seth Michaels Pollack, MD is a hematology and oncology internal medicine in Chicago, IL with 21 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. DR. Seth Michaels Pollack, MD NPI is 1528234143. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE
Graduation Year:2005

The provider's business location address is:

676 N SAINT CLAIR ST STE 850
CHICAGO, IL
ZIP 60611-124
Phone: (312) 695-6180
Fax: (312) 695-6187

The NPI 1528234143 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, carfilzomib, 1 mg (HCPCS:J9047)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg (HCPCS:J1569)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Unclassified drugs (HCPCS:J3490)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:Q0221)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Telephone medical discussion with physician, 5-10 minutes (HCPCS:99441)
• Telephone medical discussion with physician, 11-20 minutes (HCPCS:99442)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Injection of drug or substance into vein (HCPCS:96374)

The enumeration date for this NPI number is 5/3/2008 and was last updated on 1/7/2021.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: